

# Rapid Diagnosis And Risk stratification of Acute Coronary Syndrome with novel biochip array

<b>Submission date</b> 08/04/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 09/02/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 04/10/2017	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mrs Irene Knox

**Contact details**  
Craigavon Area Hospital  
68 Lurgan Road  
Portadown  
United Kingdom  
BT63 5QQ

## Additional identifiers

**Protocol serial number**  
5.2

## Study information

**Scientific Title**  
Rapid Diagnosis And Risk stratification of Acute Coronary Syndrome with novel biochip array: an observational cohort study

**Acronym**  
RADAR-ACS

## **Study objectives**

Measurement at 4 or 6 hours after symptom onset of a panel of early biomarkers of myocardial necrosis and plaque instability with a biochip assay array will be superior to measurement of the current gold standard diagnostic assay for myocardial infarction, Troponin T in patients presenting with acute coronary syndrome (ACS).

This biomarker array will also demonstrate greater independent predictive accuracy than troponin for recurrent cardiac events at 30 days and 1 year.

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Office for Research Ethics Committees Northern Ireland (ORECNI) approved on 08/05/2009 (ref: 09/NIR01/22). Protocol revision (version 5.2) and subsequent favourable opinion given on 11/11/2009.

## **Study design**

Observational cohort study

## **Primary study design**

Observational

## **Study type(s)**

Diagnostic

## **Health condition(s) or problem(s) studied**

Acute coronary syndrome

## **Interventions**

Patients will have blood sampled at admission then subsequently at time intervals 1, 2, 3, 6, 12 and 24 hours after admission. Blood will be spun and serum/plasma aliquoted then frozen at -80 degrees celsius until batch analysis. Analysis with a biochip panel consisting of Troponin I, Heart type fatty acid binding protein, Glycogen phosphorylase BB, Myoglobin, Carbonic anhydrase III and creatine kinase myocardial bands (CKMB) will be compared with 4th and 5th generation troponin T assays at each time point.

## **Intervention Type**

Device

## **Primary outcome(s)**

1. Sensitivity and specificity of investigational biomarkers when compared to troponin T at two prespecified time points after symptom onset: 4 hours, 6 hours
2. Major adverse cardiac events (MACE) defined as in hospital reinfarction (defined as further clinical signs and/or symptoms and greater than or equal to 20% increase in Troponin value 6 - 9 hours after the event), stroke, revascularisation, further admission with ACS heart failure hospitalisation, death

## **Key secondary outcome(s)**

1. Bleeding complications (assessed according to the TIMI bleeding classification)
2. In hospital revascularisation. Within this subset presenting coronary anatomy and revascularisation type will be assessed
3. Length of hospital stay

**Completion date**

04/08/2012

## Eligibility

**Key inclusion criteria**

Consecutive male and female patients over 18 years of age with a clinical diagnosis of possible acute coronary syndrome.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Unable to provide informed consent
2. Terminal malignancy
3. Patient received anticoagulant treatment or fibrinolysis prior to enrolment

**Date of first enrolment**

27/10/2009

**Date of final enrolment**

04/08/2012

## Locations

**Countries of recruitment**

United Kingdom

Northern Ireland

**Study participating centre**  
**Craigavon Area Hospital**  
Portadown  
United Kingdom  
BT63 5QQ

## Sponsor information

**Organisation**  
Southern Health and Social Care Trust (UK)

**ROR**  
<https://ror.org/02fjtnt35>

## Funder(s)

**Funder type**  
Industry

**Funder Name**  
Radox Laboratories (UK)

**Funder Name**  
Southern Health and Social Care Trust (UK)

## Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes